Inicio > Cardiología > Comportamiento de la Cardiopatía Isquémica en pacientes Hipertensos > Página 17

Comportamiento de la Cardiopatía Isquémica en pacientes Hipertensos

39. The Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013; 368:1800–8.

40. Orozco-Beltran D, Cooper RS, Gil-Guillen V, Bertomeu-Martinez V, Pita-Fernández S, Durazo-Arvizu R, et al. Tendencias en mortalidad por infarto de miocardio. Estudio comparativo entre España y Estados Unidos 1990-2006. Rev Esp Cardiol. 2012; 65:1079–85.

41. Merlos P, Lo pez-Lereu MP, Monmeneu JV, Sanchis J, Núñez J, Bonanad C, et al. Valor pronostico a largo plazo del análisis completo de los índices de resonancia magnética cardiaca tras un infarto de miocardio con elevación del segmento ST. Rev Esp Cardiol. 2013; 66:613–22.

42. Cuberas-Borro´ s G, Pineda V, Aguade´ -Bruix S, Romero-Farina G, Pizzi MN, De Leo´n G, et al. Gated-SPECT de perfusión miocárdica como técnica complementaria de la resonancia magnética para pacientes con infarto de miocardio crónico. Rev Esp Cardiol. 2013; 66:721–7.

43. Jaffe AS, Ordonez-Llanos J. Troponina cardiaca ultrasensible: de la teoría a la práctica clínica. Rev Esp Cardiol. 2013; 66:687–91.

44. Sanchis J, Bardajı´ A, Bosch X, Loma-Osorio P, Marín F, Sánchez PL, et al. Fracción amino terminal del prope´ ptido natriure´ tico cerebral y troponina ultrasensible en el dolor torácico agudo de origen incierto. Un subestudio del estudio PITAGORAS. Rev Esp Cardiol. 2013; 66:532–8.

45. Lippi G, Plebani M, Di Somma S, Monzani V, Tubaro M, Volpe M, et al. Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clin Chem Lab Med. 2012; 50:243–53.

46. Thelin J, Borna C, Erlinge D, Ohlin B. The combination of high sensitivity troponin T and copeptin facilitates early rule-out of ACS: a prospective observational study. BMC Cardiovasc Disord. 2013; 13:42.

47. Abu-Assi E, Lear P, Cabanas-Grandı´o P, Rodrı´guez-Girondo M, Raposeiras- Roubin S, Pereira-López E, et al; A comparison of the CKD-EPI. MDRD-4 and Cockcroft-Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome patients. Int J Cardiol. 2013; 67:2325–6.

48. Lo´ pez-Cuenca A, Manzano-Fernández S, Marín F, Parra-Pallares S, Navarro- Peñalver M, Montalbán-Larrea S, et al. Beta-trace protein and cystatin C as predictors of major bleeding in non-ST segment elevation acute coronary syndrome. Cir J. 2013; 77:2088–96.

49. Lim P, Moutereau S, Simon T, Gallet R, Probst V, Ferrieres J, et al. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of acute ST-Elevation Non- ST-Elevation Myocardial Infarction [FAST-MI]). Am J Cardiol. 2013; 111:31–7.

50. López-Cuenca A, Manzano-Fernández S, Lip GY, Casas T, Sanchez-Martınez M, Mateo-Martínez A, et al. Interleucina 6 y proteína C reactiva ultrasensible para la predicción de la evolucion clı´nica en síndromes coronarios agudos sin elevacio´n del segmento ST. Rev Esp Cardiol. 2013; 66:185–92.

51. Montoro-Garcıa S, Shantsila E, Tapp LD, Lo´ pez-Cuenca A, Romero AI, Hernández- Romero D, et al. Small-size circulating microparticles in acute coronary síndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis. 2013; 227:313–22.

52. Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et al. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary sındrome. J Cardiovasc Transl Res. 2013; 6: 884–98.

53. Barallobre-Barreiro J, Chung YL, Mayr M. La proteo´ mica y la metabolo´ mica: los mecanismos de la enfermedad cardiovascular y el descubrimiento de biomarcadores. Rev ESP Cardiol. 2013; 66:657–61.

54. Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-STsegment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013; 382: 605–13.

55. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–15.

56. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308:1785–94.

57. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369:999–1010.

58. Steg PG, Mehta SR, Pollack Jr CV, Bode C, Cohen M, French WJ, et al. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: The TAO randomized clinical trial. JAMA. 2013; 310:1145–55.

59. Steg PG, James SK, Atar D, Badano LP, Blomstrom Lundqvist C, Borger MA, et al. Guı´a de pra´ ctica clı´nica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevacio´n del segmento ST. Rev ESP Cardiol. 2013; 66:53.e1–46.

60. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373:723–31.

61. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–57.

62. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation.2010; 122:2131–41.

63. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013; 368:1379–87.

64. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012; 380:1482–90.

65. Su¨ rder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation. 2013; 127:1968–79.

66. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, and Ellis SG, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012; 308:2380–9.

67. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Ka¨a¨b S, et al; CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012; 33:2831–40.

68. Sharaf B, Wood T, Shaw L, Johnson BD, Kelsey S, Anderson RD, et al. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. Am Heart J. 2013; 166:134–41.

69. Sedlak TL, Lee M, Izadnegahdar M, Merz CN, Gao M, Humphries KH. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J. 2013; 166:38–44.